Data and Documentation
Open Data Policy
FAQ
EN
DE
FR
Suchbegriff
Advanced search
Project
Back to overview
Rational design of organo-ruthenium anticancer compounds with novel modes of action
English title
Rational design of organo-ruthenium anticancer compounds with novel modes of action
Applicant
Dyson Paul
Number
116374
Funding scheme
Project funding
Research institution
Laboratoire de chimie organométallique et médicinale EPFL - SB - ISIC - LCOM
Institution of higher education
EPF Lausanne - EPFL
Main discipline
Inorganic Chemistry
Start/End
01.04.2007 - 31.03.2009
Approved amount
199'026.00
Show all
Keywords (8)
Bioorganometallic; Metal pharmaceuticals; Metal-DNA interactions; Metal-protein interactions; Molecular modelling; high resolution mass spectrometry; Metal-RNA interactions; Proteomics
Lay Summary (English)
Lead
Lay summary
In this project we are developing a new type of anticancer drug that show selective toxicity in secondary cancers (metastasis). Effective drugs for these secondary cancers are not available and with surgical removal of primary cancers being well developed it is these secondary cancers are largely responsible for death in cancer patients. Based on previous research we have discovered some compounds that are highly active on secondary cancers although at high doses. It is therefore necessary to modify their structure so that they are as effective at lower doses. In order to achieve this goal we must understand in detail how these drugs work, for example, how they reach the secondary cancer sites, what they do inside the cancer to destroy it, and why they are non-toxic to healthy tissue. In this project we try to answer these questions and at the same time, we intend to modify the drugs in a rational way to improve their activity. The successful outcome of this project will be having a greater understand of the mode of action of these drugs. In addition, we hope to develop a drug that is superior to those in current use and will enter clinical trials.
Direct link to Lay Summary
Last update: 21.02.2013
Responsible applicant and co-applicants
Name
Institute
Dyson Paul
Laboratoire de chimie organométallique et médicinale EPFL - SB - ISIC - LCOM
Roethlisberger Ursula
Laboratory of Computational Chemistry and Biochemistry, EPFL SB-ISIC-LCBC-BCH
Tsybin Yury
Spectroswiss Sàrl
Employees
Name
Institute
Renfrew Anna
Laboratoire de chimie organométallique et médicinale EPFL - SB - ISIC - LCOM
Tapavicza Enrico
Department of Chemistry University of California, Irvine
Campomanes Pablo
Laboratoire de chimie et biochimie computationnelles EPFL - SB - ISIC - LCBC
Gossens Christian
Associated projects
Number
Title
Start
Funding scheme
125173
Rational design of organo-ruthenium anticancer compounds with novel modes of action
01.04.2009
Project funding
107941
Rational design of organo-ruthenium anticancer compounds with novel modes of action
01.04.2005
Project funding
121262
R'Equip - Amélioration de deux spectromètres RMN 9.4T par des consôles digitales
01.07.2008
R'EQUIP
125173
Rational design of organo-ruthenium anticancer compounds with novel modes of action
01.04.2009
Project funding
-